Dr. Reddy’s launches Parkinson’s disease drug
HYDERABAD, India — Dr. Reddy’s Labs has launched a drug for treating Parkinson’s disease, the company said Thursday.
Dr. Reddy’s introduced ropinirole hydrochloride extended-release tablets in the 2-mg, 4-mg, 6-mg, 8-mg and 12-mg strengths. The 2-mg, 4-mg and 6-mg strengths will be available in 30- and 90-count bottle sizes, while the other two strengths will be available in 30-count bottles.
The drug is a generic version of GlaxoSmithKline’s Requip XL, which had sales of $58 million during the 12-month period ended in March, according to IMS Health.
JDRF, BD extend partnership to accelerate development of proprietary glucose-sensing technology
FRANKLIN LAKES, N.J. — A diabetes research organization and a medical technology company have extended their partnership.
The Juvenile Diabetes Research Foundation and medical supply manufacturer BD — which previously collaborated to enhance the use of insulin pumps in patients with Type 1 diabetes — said they will accelerate the development of BD’s proprietary glucose-sensing technology, which has shown promise in providing very accurate and reliable continuous glucose information.
"BD understands and believes in JDRF’s commitment to and excitement about the prospects of developing better technologies in a relatively short timeframe to benefit people with diabetes," JDRF president and CEO Jeffrey Brewer said. "BD is well positioned to address the patient need given its heritage in injection- and infusion-based drug delivery. We look forward to working with BD on this initiative."
NACDS appoints Tom O’Donnell as VP federal government affairs
ALEXANDRIA, Va. — The chief of staff for Rep. Steve Rothman, D-N.J., is taking on a new role.
The National Association of Chain Drug Stores announced that Tom O’Donnell is joining the organization as VP federal government affairs, where he will spearhead the strategic direction for and overall management of NACDS’ federal legislative advocacy program, including serving as a resource and advocate on Capitol Hill and advancing the association’s grassroots and political affairs activities, NACDS president and CEO Steve Anderson said.
O’Donnell will begin his new position on July 9 and will report to Carol Kelly, NACDS SVP government affairs and public policy.
"We are thrilled that Tom will soon join NACDS’ highly regarded and highly effective government affairs and public policy team," Anderson said. "Tom’s extensive legislative and political experience position him exceedingly well to serve as NACDS’ chief legislative advocate for community pharmacy. As the face of neighborhood health care, community pharmacy plays a vital role in improving patient health and reducing costs in the healthcare delivery system. With Tom on board, NACDS will further bolster its commitment to ensuring pro-patient, pro-pharmacy policy solutions at the federal level."